Integrity Coronary Stent System    

Log In
 
 

Forgot Your Password?
 


Not a member? Click here!

Status of Primary PCI in the US: Lessons From NRMI (Comparison With Thrombolysis, Impact of Time, Magnitude, Reasons for Delays, and More)
Low-Molecular Weight Heparins in STEMI: The CREATE Trial
Antiplatelet Effects of Anticoagulants: Potential of Oral Factor Xa Inhibitors to Prevent Arterial Thrombosis
The Role of Adenosine as Adjunctive Therapy in Acute Myocardial Infarction
Fondaparinux in ACS






 

 

PCI for CTOs: A Shifting Paradigm

Treatment of CTOs with PCI has not been universally adopted due to a combination of technical issues and skepticism regarding its clinical benefits. Analysis of data from the British cardiac audit database, including 13,443 patients, has indicated that successful CTO PCI is associated with improved survival.

For more, click here

 

 

 

What's Next for Niacin?

The risk of adverse vascular events in patients with vascular disease remains significant despite optimal medical therapy. Niacin has been suggested to reduce this risk. A study of 25,673 patients with vascular disease has shown that the combination of niacin plus laropiprant, designed to reduce LDL and increase HDL, has been shown not only to reduce the risk of major vascular events but also to increase the risk of serious adverse events such as diabetes mellitus and bleeding.

For more, click here

 

 

 

Antipsychotic Medication & Risk of MI

Analysis of data from 56,910 patients has demonstrated that the use of antipsychotic medication is associated with a transient increase in the risk of MI. The risk increased with increases in the dosage of the drug, male patients, elderly patients, and patients with dementia. The risk may be mediated through dopamine type 3 receptor blockades.

For more, click here

 

 

 

Statins & Diabetes Link Strengthens

The diabetes risk associated with statin has been intensely debated. An Italian observational study of 115,709 patients has shown that the risk of new-onset diabetes increases as adherence with statin therapy increases. The authors have estimated that 280 patients require treatment with statins to cause 1 case of diabetes per year.

For more, click here

 

<
||
>















CRT2013
Untitled Document
 
Complementary role of percutaneous and surgical circulatory support in cardiogenic shock: Introduction and objectives
- Holger Thiele, MD
How to Solve a Bifurcation Puzzle?: Anatomical, Physiological, and Clinical Relevance of Bifurcation Lesions
- Bon-Kwon Woo, MD, PhD
The Heart Team: Challenges and Strategies for Success
- David J. Cohen, MD, MSc
Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study: (the cardiac-RESCUE program)
- Sylvain Beurtheret, MD, et al.
2013 ACS: Year in Review
- Robert P. Giugliano, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

Vinayak Bapat, MDValve in Valve
- Vinayak Bapat, MD
 Click here to visit the WEBEX archives


Long-Term Follow-Up of Elective Chronic Total Coronary Occlusion Angioplasty: Analysis From the U.K. Central Cardiac Audit Database.
S George, et al.
JACC 2014; 64:235-243
Beta-Blocker Therapy and Cardiac Events Among Patients With Newly Diagnosed Coronary Heart Disease.
C Andersson, et al.
JACC 2014; 64:247-252
Aspirin Therapy in Primary Cardiovascular Disease Prevention: A Position Paper of the European Society of Cardiology Working Group on Thrombosis.
S Halvorsen, et al.
JACC 2014; 64:319-327
Association Between Antipsychotic Use and Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover Study.
S Lin, et al.
Circ 2014; 130:235-243
Randomized, Controlled Trial to Improve Self-Care in Patients With Heart Failure Living in Rural Areas.
K Dracup, et al.
Circ 2014; 130:256-264
Evaluation of Interval Times From Onset to Reperfusion in Patients Undergoing Endovascular Therapy in the Interventional Management of Stroke III Trial.
M Goyal, et al.
Circ 2014; 130:265-272
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients.
The HPS2-THRIVE Collaborative Group.
NEJM 2014; 371:203-212
Effect of Renin-Angiotensin System Inhibitors on Long-Term Survival in Patients Treated With Beta Blockers and Antiplatelet Agents After Acute Myocardial Infarction (from the MONICA/KORA Myocardial Infarction Registry).
U Amann, et al.
AJC 2014; 114:329-335
Effect of Myocardial Perfusion Pattern on Frequency and Severity of Mitral Regurgitation in Patients With Known or Suspected Coronary Artery Disease.
S Volo, et al.
AJC 2014; 114:355-361
Impact of Smoking Status on Platelet Function and Clinical Outcomes With Prasugrel vs. Clopidogrel in Patients With Acute Coronary Syndromes Managed Without Revascularization: Insights From the TRILOGY ACS Trial.
J Corne, et al.
AHJ 2014; 168:76-87
Delay in Reperfusion With Transradial Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Might Some Delays Be Acceptable?
N Wimme, et al.
AHJ 2014; 168:103-109




Poll Archives

OCTAVIA Study
G. Guagliumi, MD, et al.
Will preventive intervention outweigh the cardiovascular protection of antithrombotic and lipid-lowering treatment?
M. Valgimigli, MD, PhD
PRAGUE-16 pilot study
Petr Widimsky, MD, et al.
SAPIEN 3 Trial
John Webb, MD
Century II Trial
William Wijns, MD, et al.



Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
BIOFLOW-II Trial
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD
The RESOLUTE Program: today and tomorrow
Sigmund Silber, MD, PhD
RESOLUTE International Trial
F-J. Neumann, MD, et al.
Primary Results Following Percutaneous Coronary Intervention with the 38mm Resolute Zotarolimus-eluting Stent
Shirish Hiremath, MD, et al.
Two Year Outcomes Following Implantation of the Resolute Zotarolimus-eluting Stent in Small (less or equal to 2.5 mm) Vessels
Ronald Caputo, MD



7/18/2014
InspireMD Announces Successful Completion of CGuardTM CARENET (CARotid Embolic protection study using microNET) Trial

7/18/2014
Spectranetics Announces Launch of AngioScore’s 200-mm AngioSculpt PTA Scoring Balloon Catheters

7/18/2014
BIOTRONIK Announces First Enrollments to BIOFLEX PEACE Registry

7/18/2014
Boston Scientific Receives CE Mark For The New 25 mm Lotus™ Valve System

7/10/2014
Boehringer Ingelheim’s Investigational Antidote for Pradaxa Receives FDA Breakthrough Therapy Designation

7/10/2014
Infraredx Announces the First Patient Enrolled in the PROSPECT II Study on the Detection and Treatment of the Vulnerable Plaques Suspected to Cause Heart Attacks

7/10/2014
Spectranetics Completes Acquisition of AngioScore

7/10/2014
First European Experience with Innovative Guidewire at St George’s Hospital London, UK

7/10/2014
Thoratec Acquires Apica Cardiovascular

7/10/2014
The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

7/10/2014
Toshiba’s New Cardiovascular X-ray System Provides Uncompromised Imaging to Meet Facilities’ Clinical Needs

7/10/2014
480 Biomedical Awarded $1 Million Phase II NHLBI Contract to Advance Bioresorbable Scaffold for Pediatric Pulmonary Artery Stenosis

7/9/2014
Micell Technologies Adds to Portfolio of Intellectual Property Protection

6/16/2014
Circulatory System Devices Advisory Panel Provides a Unanimous Favorable Recommendation to FDA for the Lutonix® Drug Coated Balloon

6/12/2014
Study Demonstrates Risk Reduction in Pediatric Catheterizations

6/12/2014
Clinical and Economic Data Presented From CSI’s ORBIT II Coronary Study

6/12/2014
Stentys to Acquire Cappella Peel Away Stent Delivery Technology

6/12/2014
Boston Scientific Initiates RESPOND Postmarket Registry of Lotus TAVR System
ACS & AMI
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login


Copyright © 2014, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb